Multi-component prime-boost Chlamydia trachomatis vaccination regimes induce antibody and T cell responses and accelerate clearance of infection in a non-human primate model

It is of international priority to develop a vaccine against sexually transmitted Chlamydia trachomatis infections to combat the continued global spread of the infection. The optimal immunization strategy still remains to be fully elucidated. The aim of this study was to evaluate immunization strategies in a nonhuman primate (NHP) model. Cynomolgus macaques (Macaqua fascicularis) were immunized following different multi-component prime-boost immunization-schedules and subsequently challenged with C. trachomatis SvD in the lower genital tract. The immunization antigens included the recombinant protein antigen CTH522 adjuvanted with CAF01 or aluminium hydroxide, MOMP DNA antigen and MOMP vector antigens (HuAd5 MOMP and MVA MOMP). All antigen constructs were highly immunogenic raising significant systemic C. trachomatis-specific IgG responses. In particularly the CTH522 protein vaccinated groups raised a fast and strong pecificsIgG in serum. The mapping of specific B cell epitopes within the MOMP showed that all vaccinated groups, recognized epitopes near or within the variable domains (VD) of MOMP, with a consistent VD4 response in all animals. Furthermore, serum from all vaccinated groups were able to in vitro neutralize both SvD, SvE and SvF. Antibody responses were reflected on the vaginal and ocular mucosa, which showed detectable levels of IgG. Vaccines also induced C. trachomatis-specific cell mediated responses, as shown by in vitro stimulation and intracellular cytokine staining of peripheral blood mononuclear cells (PBMCs). In general, the protein (CTH522) vaccinated groups established a multifunctional CD4 T cell response, whereas the DNA and Vector vaccinated groups also established a CD8 T cells response. Following vaginal challenge with C. trachomatis SvD, several of the vaccinated groups showed accelerated clearance of the infection, but especially the DNA group, boosted with CAF01 adjuvanted CTH522 to achieve a balanced CD4/CD8 T cell response combined with an IgG response, showed accelerated clearance of the infection.

[1]  J. Christensen,et al.  Th1/Th17 T cell Tissue-Resident Immunity Increases Protection, But Is Not Required in a Vaccine Strategy Against Genital Infection With Chlamydia trachomatis , 2021, Frontiers in Immunology.

[2]  Yun Feng,et al.  A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications , 2021, Frontiers in Cell and Developmental Biology.

[3]  M. Starnbach,et al.  Gamma Interferon Is Required for Chlamydia Clearance but Is Dispensable for T Cell Homing to the Genital Tract , 2020, mBio.

[4]  P. Andersen,et al.  Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge , 2020, npj Vaccines.

[5]  P. Andersen,et al.  Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. , 2019, The Lancet. Infectious diseases.

[6]  G. Zhong,et al.  Chlamydia muridarum Induces Pathology in the Female Upper Genital Tract via Distinct Mechanisms , 2019, Infection and Immunity.

[7]  J. Tregoning,et al.  Adjuvanted influenza vaccines , 2018, Human vaccines & immunotherapeutics.

[8]  P. Andersen,et al.  Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis , 2017, Front. Immunol..

[9]  Alexandra Nunes,et al.  A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances Chlamydia trachomatis Clearance , 2016, Front. Immunol..

[10]  M. Plenderleith,et al.  Induction of partial immunity in both males and females is sufficient to protect females against sexual transmission of Chlamydia , 2015, Mucosal Immunology.

[11]  Marleen Temmerman,et al.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting , 2015, PloS one.

[12]  A. Brzozowski,et al.  Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies , 2015, PloS one.

[13]  P. Andersen,et al.  Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. , 2015, The Journal of infectious diseases.

[14]  B. Nicholson,et al.  The Contribution of Chlamydia-Specific CD8+ T Cells to Upper Genital Tract Pathology , 2015, Immunology and cell biology.

[15]  P. Timms,et al.  Evaluation of intra‐ and extra‐epithelial secretory IgA in chlamydial infections , 2014, Immunology.

[16]  Arlo Z. Randall,et al.  Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques. , 2014, Journal of proteomics.

[17]  H. Caldwell,et al.  CD8+ T Cells Define an Unexpected Role in Live-Attenuated Vaccine Protective Immunity against Chlamydia trachomatis Infection in Macaques , 2014, The Journal of Immunology.

[18]  B. Dodet.  Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies. , 2014, Vaccine.

[19]  P. Timms,et al.  Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens , 2014, Immunology and cell biology.

[20]  David C. Gondek,et al.  CD4+ T Cells Are Necessary and Sufficient To Confer Protection against Chlamydia trachomatis Infection in the Murine Upper Genital Tract , 2012, The Journal of Immunology.

[21]  D. Aronoff,et al.  Nonhuman Primate Models Used to Study Pelvic Inflammatory Disease Caused by Chlamydia trachomatis , 2011, Infectious diseases in obstetrics and gynecology.

[22]  B. Arulanandam,et al.  Tumor Necrosis Factor Alpha Production from CD8+ T Cells Mediates Oviduct Pathological Sequelae following Primary Genital Chlamydia muridarum Infection , 2011, Infection and Immunity.

[23]  N. Low,et al.  Risk of sequelae after Chlamydia trachomatis genital infection in women. , 2010, The Journal of infectious diseases.

[24]  Robert E. Johnson,et al.  Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. , 2010, The Journal of infectious diseases.

[25]  F. Eko,et al.  Role of T lymphocytes in the pathogenesis of Chlamydia disease. , 2009, The Journal of infectious diseases.

[26]  David C. Gondek,et al.  T Cell Responses in the Absence of IFN-γ Exacerbate Uterine Infection with Chlamydia trachomatis , 2009, The Journal of Immunology.

[27]  J. Christensen,et al.  CD4 and CD8 T Cell Responses to the M. tuberculosis Ag85B-TB10.4 Promoted by Adjuvanted Subunit, Adenovector or Heterologous Prime Boost Vaccination , 2009, PloS one.

[28]  S. Hillier,et al.  Preclinical Safety Assessments of UC781 Anti-Human Immunodeficiency Virus Topical Microbicide Formulations , 2007, Antimicrobial Agents and Chemotherapy.

[29]  P. Andersen,et al.  Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. , 2005, Biochimica et biophysica acta.

[30]  D. Longbottom,et al.  Animal chlamydioses and zoonotic implications. , 2003, Journal of comparative pathology.

[31]  F. Eko,et al.  Fc receptor regulation of protective immunity against Chlamydia trachomatis , 2002, Immunology.

[32]  R. Brunham,et al.  Priming with Chlamydia trachomatis Major Outer Membrane Protein (MOMP) DNA followed by MOMP ISCOM Boosting Enhances Protection and Is Associated with Increased Immunoglobulin A and Th1 Cellular Immune Responses , 2000, Infection and Immunity.

[33]  K. Barnhart,et al.  Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. , 1999, Vaccine.

[34]  M. Ward,et al.  Studies in Knockout Mice Reveal that Anti‐Chlamydial Protection Requires TH1 Cells Producing IFN‐γ: Is this True for Humans? , 1997, Scandinavian journal of immunology.

[35]  W. V. Van Voorhis,et al.  Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring , 1997, Infection and immunity.

[36]  H. Caldwell,et al.  Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. , 1997, Journal of immunology.

[37]  E. Peterson,et al.  Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. , 1997, Vaccine.

[38]  R. Morrison,et al.  Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection , 1995, Infection and immunity.

[39]  H. Caldwell,et al.  Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection , 1995, Infection and immunity.

[40]  H. Caldwell,et al.  CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract , 1995, Infection and immunity.

[41]  R. Rank,et al.  Role of CD8 T cells in primary Chlamydia infection , 1995, Infection and immunity.

[42]  H. Caldwell,et al.  Workshop on in vitro neutralization of Chlamydia trachomatis: summary of proceedings. , 1993, The Journal of infectious diseases.

[43]  K. Holmes,et al.  Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix , 1983, Infection and immunity.

[44]  H. Caldwell,et al.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis , 1981, Infection and immunity.

[45]  H. T. Walworth.  Summary of Proceedings , 1935, Proceedings of the Prehistoric Society.